Results 31 to 40 of about 14,551 (185)

Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option

open access: yesMolecular Cancer, 2010
Background Myxoid liposarcoma is a relatively common malignant soft tissue tumor, characterized by a (12;16) translocation resulting in a FUS-DDIT3 fusion gene playing a pivotal role in its tumorigenesis.
Szuhai Karoly   +5 more
doaj   +1 more source

Axitinib has antiangiogenic and antitumorigenic activity in myxoid liposarcoma [PDF]

open access: yes, 2016
Myxoid liposarcoma is a rare form of soft-tissue sarcoma. Although most patients initially respond well to treatment, approximately 21% relapse, highlighting the need for alternative treatments.
Kerr, Lauren T.   +7 more
core   +1 more source

The first case of rectal myxoid liposarcoma identified by FUS-DDIT3 fusion, presenting as a submucosal tumor with erosion

open access: yesHuman Pathology: Case Reports, 2018
We experienced a 58-year-old Japanese female complaining of bleedings at defecation for about one year. Endoscopy revealed an Ip submucosal tumor (SMT) at the rectum.
Hiroshi Kono   +7 more
doaj   +1 more source

Clinical features of multiply recurrent retroperitoneal liposarcoma: A single-center experience

open access: yesAsian Journal of Surgery, 2021
Background: To elucidate the clinicopathological features of multiply recurrent retroperitoneal liposarcoma referred to a tertiary center. Methods: We retrospectively analyzed the clinical data of 40 patients with pathologically proven primary ...
Noriyuki Masaki   +5 more
doaj   +1 more source

FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma

open access: yesFrontiers in Oncology, 2022
Myxoid liposarcoma is one of the most common sarcoma entities characterized by FET fusion oncogenes. Despite a generally favorable prognosis of myxoid liposarcoma, chemotherapy resistance remains a clinical problem.
Soheila Dolatabadi   +11 more
doaj   +1 more source

Myxoid liposarcoma of bladder

open access: yesInternational Journal of Surgery Case Reports, 2021
Abstract Introduction Myxoid liposarcoma of the bladder is a rare mesenchymal tumor which is difficult to diagnose and carries a poor prognosis. The primary treatment is complete surgical resection which is usually followed by adjuvant chemotherapy.
Chudal, Sampanna   +5 more
openaire   +2 more sources

[Myxoid liposarcoma].

open access: yesRevue medicale de Liege, 2009
Soft-tissue sarcoma is a rare pathology. Due to restricted symptomatology, the diagnosis is often late. Any soft tissues swelling requires at first an ultrasound exam and a radiography, though MRI remains the most appropriate investigation. Treatment will be selected according to the tumor type and its histological grading, these parameters being ...
F, Douchamps, W, Kurth, J M, Crielaard
openaire   +3 more sources

Recurrent massive myxoid liposarcoma in retroperitoneum 10 years post initial operation

open access: yesIJU Case Reports, 2019
Introduction Myxoid liposarcoma tends to be a relatively good prognosis. Follow‐up is recommended once a year from the 5th year after surgery. Case presentation A 48‐year‐old man had a massive retroperitoneal tumor, measuring approximately 20 cm ...
Takamasa Horiuchi   +4 more
doaj   +1 more source

Late-onset meningeal metastases in liposarcoma: A case report and review of the literature [PDF]

open access: yes, 2006
Intracranial metastases from liposarcoma are rare and almost always preceded by the development of systemic tumour spread. We report here a case of liposarcoma with spread to the cranial nervous system 23 years after treatment of the primary tumour.
White, J.   +3 more
core   +1 more source

Successful resection of a giant thoracic myxoid liposarcoma

open access: yes, 2018
Primary liposarcoma is an extremely rare disease. We report a case of giant thoracic myxoid liposarcoma that occupied the whole left hemithorax and was successfully resected.
Wei Chieng Pui   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy